The R&D Leadership Summit convenes industry experts and leaders from the biopharmaceutical field to delve into pivotal topics shaping the trajectory of research and development.
On March 4th, our CEO, Colin Hill, will be part of a panel to discuss the transformative potential of AI and its profound implications in drug discovery. The discussion will center around the intricate interplay between AI, regulatory science, and clinical trials operations.
Joining Colin on the panel fellow panelists: Roy Baynes, EVP and CMO at Eikon Therapeutics; Najat Khan, PhD, Chief Data Science Officer and Global Head of Strategy & Portfolio Organization, R&D, at J&J Innovative Medicine; Alexandra Snyder, MD, EVP R&D, Generate:Biomedicines; and Frank Nestle, Global Head of Research and CSO at Sanofi.
For further details on this summit, visit: https://rdlsummit.com/